OBJECTIVES: Before 2006 bed occupancy rates during winter periods were above the general acceptance threshold (85%) in Jesse Hospital paediatric ward (Hasselt, Belgium), with peaks above 100%. This causes pressure on bed and people management expressed in bad QoC scores. We evaluated two methods to improve the scores and their investment costs. METHODS: Option A is extending the number of beds in the ward, whereas the unit operating cost is expected to be higher over the whole winter season. Option B is introducing rotavirus vaccination to infants with high coverage in the catchment area. A hospital with 36 paediatric beds was set up in 2007, and a comparison study was carried out per an average of 6 years (2004-2009) were collected, including pre- and post-introduction of the vaccine in 2006. Estimated birth cohort was 7,000/year in the catchment area. For Option A total cost per year was calculated referring to the observed pre-vaccination period. For Option B cost of vaccinating the birth cohort with implementation of the whole hospital savings was calculated applying the observed post-vaccination period. Total cost per year for each option was compared. RESULTS: Option A: extending infant beds was the least cost-effective way to lower the threshold costs about €436,000/year and the threshold may still sometimes be exceeded. Option B: vaccination program in the area costs €420,000/year, leading to a 41% reduction in the number of bed-days for gastro-enteritis during the winter, equivalent to an overall 82% bed occupancy/day, being below the threshold throughout winter. CONCLUSIONS: Option B with vaccination is cheaper than option A with extra beds. Moreover it maintains the occupancy rate below the safety threshold during the whole winter period, and thus guarantees better QoC scores in the pediatric ward.

PIN120

COST-EFFECTIVENESS ANALYSIS OF PHID-CV ROUTINE VACCINATION PROGRAMME COMPARED TO PCV-13 IN PORTUGAL

Cestinha V1, André S1, Van de Velde N2, Correia V1, André S1, Van de Velde N2

OBJECTIVES: To estimate the incremental cost-effectiveness ratio (ICER) of the pneumococcal conjugate vaccine (PCV-13) compared to the 13-valent pneumococcal conjugate vaccine (PHID-CV) in routine infant vaccination in Portugal. METHODS: The cost-effectiveness analysis (CEA) is based on a Markov model simulating meningitis, bacteraemia, pneumonia and acute otitis media (AOM) in a Portuguese birth cohort until 10 years of age. CEA is performed from the National Health Service (NHS) perspective with 5% discounting on both costs and effects. The model has been parameterized using local serotype distribution, disease incidence and direct medical costs. Disutility weights come from international published literature and vaccine efficacy assumptions come from large randomized controlled trials. Model parameters have been validated by a panel of experts. Base case scenario assumes vaccinating children in 4, 12 and 16 months of age with 95% coverage of the whole birth cohort. One-way and probabilistic sensitivity analyses were carried out to identify most influential parameters and estimate conjoint parameter uncertainty, respectively. RESULTS: Assuming both vaccines have the same price, the model predicts that PHID-CV is the dominant intervention resulting in a health gain of 7 Quality-Adjusted Life Years (QALYs) and a saving of 332,151€ over PCV-13 (ICER = -45,216€/QALY). One-way sensitivity analysis shows ICER is very sensitive to efficacy against Streptococcus pneumoniae and Haemophilus influenzae, general practices visits and disutility, all related to AOM. The probabilistic sensitivity analysis confirms the robustness of our results with 95% of simulations showing that PHID-CV (ICER is below 30,000€/QALY compared to PCV-13. CONCLUSIONS: Using PHID-CV in the routine vaccination program for children in Portugal could generate more health benefits and savings for NHS, even when considering parity price versus PCV-13. These savings could then be used to implement other public health measures such as a catch-up program to reduce inequalities in older cohorts.

RESEARCH POSTER PRESENTATIONS – SESSION IV

DISEASE – SPECIFIC STUDIES

DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies

PB1

RISK OF NEW-ONSET DIABETES ASSOCIATED WITH CONCOMITANT ANTIDEPRESSANT, INHALED CORTICOSTEROIDS, AND STATIN USE AMONG MEDICAID BENEFICIARIES WITH COPD

Ageina M1, Sambunaris L2

2RTI Health Solutions, RTP, NC, USA, 2West Virginia University, Morgantown, WV, USA

OBJECTIVES: Multiple medication use is common among individuals with Chronic Obstructive Pulmonary Disease (COPD). Specifically, use of antidepressants, inhaled corticosteroids (ICS), and statins may place individuals with COPD at high risk for new-onset diabetes. We examined the relationship between use of medications (antidepressants, ICS, and statins) and new-onset diabetes among Medicaid beneficiaries with COPD. METHODS: We used a retrospective longitudinal cohort design using multiple years (2005-2008) of Medicaid claims of beneficiaries with newly diagnosed COPD (n = 15,287). We identified receipt of antidepressants, ICS, and statins among Medicaid recipients using the International Classification of Diseases-9th-Clinical Modification (250.x) codes. Chi-square tests of independence and multivariate logistic regressions were used to examine the relationship between medication use and new-onset diabetes. Instrumental variable techniques were used to control for selection bias in statin use. We conducted analysis using SAS v 9.3 and STATA v11.11. RESULTS: Among Medicaid beneficiaries with newly-diagnosed COPD, 6.3% had new-onset diabetes. After controlling for baseline characteristics, adults with ICS (AOR: 1.23, 95% CI 1.07, 1.41) and statins (AOR: 1.48, 95% CI 1.27, 1.72) had greater risk of new-onset diabetes compared to those without ICS and statins. However, analyses using combined medication categories revealed that only adults with statin use in combination with antidepressants and ICS or ICS alone were more likely to have new-onset diabetes. Instrumental variable adjusted regression which controlled for selection bias in statin use revealed no significant association between statin use and new-onset diabetes. We suggest that using these combinations (antidepressants, ICS and statins) was not associated with new-onset diabetes. However, as individuals with COPD are at higher risk of developing new-onset diabetes due to shared risk factors, further research with longer follow-up and randomized design is required to evaluate the safety of these medications.

PB2

THE ASSOCIATION OF WAIST CIRCUmFERENCE AND MICROVASCULAR COMPLICATIONS IN DIABETIC PATIENTS IN AN ASIAN POPULATION

Azmi S1, Feisul M1, Abdali A1, Goh A1, Abdul Aziz SH

1Azmi Baruah Consulting, Petaling Jaya, Malaysia, 2Ministry of Health, Malaysia, Putrajaya, Malaysia

OBJECTIVES: The aim of the study was to explore the association of waist circumference with microvascular complications in Malaysian patients with type 2 diabetes mellitus. METHODS: Patients followed up in Malaysian public sector primary care clinics contained in the National Diabetes Registry in the year 2012. Variables of interest were the presence of microvascular complications, namely nephropathy and retinopathy. Multiple logistic regression was used to explore the association between presence of microvascular complications and waist circumference, which was adjusted for age, sex, duration of diabetes, systolic blood pressure, insulin use, total cholesterol and HbA1c. RESULTS: A total of 114,719 patients with type 2 diabetes were included in the study. The mean waist circumference was 59.8 cm (SD: 11.2) with mean duration of diabetes of 6.8 years (SD: 5.1). Male patients comprised 39.9% of the sample population and 83.5% of the patients were on metformin therapy (BMI ≥ 22 kg/m2). Nephropathy and retinopathy were present in 9.1% and 7.9% of patients respectively. The mean waist circumference was 91.4 cm (SD: 11.8) for males and 90.8 cm (SD: 11.8) for females; while 78.4% of the patients had waist circumference ≥ 94 cm for men and ≥ 80 cm for women. High waist circumference was found to be significantly associated with nephropathy (adj. OR 1.005; p-value <0.001; 95% CI 1.003-1.008) after adjusting for confounding factors. However, waist circumference was not significantly associated with retinopathy (adj. OR 0.998; p-value =0.085). CONCLUSIONS: Analysis showed that patients with higher waist circumference were more likely to have nephropathy than patients with lower waist circumference. The analysis also showed that waist circumference was not associated with retinopathy in the study population.

PB3

RELATIONSHIP BETWEEN GLYCEMIC BURDEN AND MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A REAL-WORLD STUDY IN THE PHARMO DATABASE NETWORK

Overbeek J1, van Wijngaarden R1, Diels F2, Schibert A3, Straylight A4, Hesse H1, Steyerberg EW1, Hensel M4, Nijpels G5, Herings R1

1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Janssen Research & Development, Beerse, Belgium, 3Janssen-Cilag Poland, Warsaw, Poland, 4Erasmus MC, Rotterdam, The Netherlands, 5Janssen-Cilag A/S, Birkerød, Denmark, 6EMGO Institute, VU Medical Centre, Amsterdam, The Netherlands

OBJECTIVES: The relationship between glycaemic burden and micro- and macrovascular complications among patients with type 2 diabetes mellitus (T2DM) was investigated using real-world data. METHODS: We used a retrospective longitudinal dynamic cohort design with time-dependent Cox proportional hazards model, with glycaemic burden entered in the model as a time-varying covariate. Glycaemic burden was defined based on the extent and duration of time over a patient’s glycated haemoglobin (A1c) measurements (A1c ≥ 1.38, 1.76, and 2.22, respectively), diabetic foot (HR: 1.08, 1.24, and 1.55, respectively), nephropathy (HR: 1.11, 1.16, and 1.14, respectively), and cerebrovascular disease (HR: 1.16, 1.28, and 1.36, respectively). For CAD, a significantly higher risk was found only for patients with ≥3 x SD and ≥3 x SD (HR: 1.12 and 1.32, respectively). CONCLUSIONS: Results of this study show that GBY is an important predictor of micro- and macrovascular complications and thus may be important to consider in T2DM management.

PB4

EXEMEDidine ONCE WEEKLY PLUS METForMINFor THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A NETWORK META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

Kenny N1, Lozano-Otorga G2, Bennett H1, Johnson K1, Shaunik A3, Grandy S5, Karzbrun R8

1ICON plc, Toronto, ON, Canada, 2ICON, Vancouver, BC, Canada, 3AstraZeneca, Möln达尔, Sweden, 4Astrazeneca, Gatchina, MD, USA, 5Astrazeneca Pharmaceuticals, LP, Gatchina, Russia, 6MD Anderson Cancer Center, Houston, TX, 7Novo Nordisk, Bagsvaerd, Denmark, 8University of Bath, Bath, UK

OBJECTIVES: The objective of this study is to determine the relative efficacy and tolerability of exenatide 2mg once-weekly (EQW), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), compared to other GLP-1 RAs for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on metformin (MET). METHODS: A systematic literature review was